MediSearch Clinical Trials

Summary

MediSearch Clinical Trials is a medical facility located in Saint Joseph, Missouri. This center is recognized for care of Atopic Dermatitis, Medical Device Dermatitis, Skin Conditions, Acne, Hidradenitis Suppurativa and other specialties. MediSearch Clinical Trials is involved with conducting 57 clinical trials across 58 conditions. There are 1 research doctors associated with this hospital, such as Melody Stone.

Top PIs

Clinical Trials running at MediSearch Clinical Trials

Atopic Dermatitis

Hidradenitis Suppurativa

Prurigo Nodularis

Acne

Medical Device Dermatitis

Skin Conditions

Dermatitis

Eczema

Vitiligo

Skin Diseases

Tapinarof Cream

for Atopic Dermatitis

The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.

Recruiting

2 awards

Phase 3

2 criteria

Upadacitinib

for Eczema

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD. Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib 15mg or dupilumab 300mg. Based on the participants response to upadacitinib 15mg, they may have their dose increased to upadacitinib 30mg after 2 weeks. In Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 200 adult participants ages 18 to less than 64 with moderate to severe AD who are current users of dupilumab and had a history of inadequate response to dupilumab will be enrolled at up to 130 sites worldwide. The study is comprised of a 35-day Screening Period, an 8-week Open-Label Period 1 and a 24-week Open-Label Period 2 for participants that completed Period 1. Participants will receive upadacitinib oral tablets once daily or dupilumab subcutaneous (SC) injection every other week for 32 weeks and followed for 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Recruiting

2 awards

Phase 3

2 criteria

Ruxolitinib Cream

for Eczema

The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis.

Recruiting

1 award

Phase 3

3 criteria